BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 8201378)

  • 21. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Azli N; Fandi A; Bachouchi M; Rahal M; Lianes P; Wibault P; Boussen H; Eschwege F; Armand JP; Cvitkovic E
    Cancer J Sci Am; 1995; 1(3):222-9. PubMed ID: 9166480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy and operation for invasive thymoma.
    Rea F; Sartori F; Loy M; Calabrò F; Fornasiero A; Daniele O; Altavilla G
    J Thorac Cardiovasc Surg; 1993 Sep; 106(3):543-9. PubMed ID: 8361199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Giaccone G; Ardizzoni A; Kirkpatrick A; Clerico M; Sahmoud T; van Zandwijk N
    J Clin Oncol; 1996 Mar; 14(3):814-20. PubMed ID: 8622029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone.
    Yokoi K; Matsuguma H; Nakahara R; Kondo T; Kamiyama Y; Mori K; Miyazawa N
    J Thorac Oncol; 2007 Jan; 2(1):73-8. PubMed ID: 17410014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.
    Overmoyer B; Silverman P; Holder LW; Tripathy D; Henderson IC
    Clin Breast Cancer; 2005 Jun; 6(2):150-7. PubMed ID: 16001993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study.
    Sparano JA; Neuberg D; Glick JH; Robert NJ; Goldstein LJ; Sledge GW; Wood W
    J Clin Oncol; 1997 May; 15(5):1880-4. PubMed ID: 9164198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial.
    Loehrer PJ; Wang W; Johnson DH; Aisner SC; Ettinger DS;
    J Clin Oncol; 2004 Jan; 22(2):293-9. PubMed ID: 14722038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience.
    Hanna N; Gharpure VS; Abonour R; Cornetta K; Loehrer PJ
    Bone Marrow Transplant; 2001 Sep; 28(5):435-8. PubMed ID: 11593315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
    J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose adriamycin (ADM) and cis-platinum (DDP) in advanced soft-tissue sarcomas and invasive thymomas. A pilot study.
    Klippstein TH; Mitrou PS; Kochendörfer KJ; Bergmann L
    Cancer Chemother Pharmacol; 1984; 13(2):78-81. PubMed ID: 6540630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
    J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma.
    Tamiya A; Matsumura A; Tsuji T; Morimoto M; Asami K; Okishio K; Shimizu S; Yoon HE; Atagi S; Akira M; Kitaichi M; Kawaguchi T
    Anticancer Res; 2014 Apr; 34(4):2023-7. PubMed ID: 24692742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemotherapy of thymoma].
    Monden Y; Uyama T; Kimura S; Takahashi K
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2019-24. PubMed ID: 2221924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
    Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
    Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.